Intra-lesional low-dose interferon α2a therapy for primary cutaneous marginal zone B-cell lymphoma

Leukemia and Lymphoma

Volumn 47, Issue 5, 2006, Pages 865-869

  Cozzio, Antonio ^a   Kempf, Werner ^a   Schmid Meyer, Regula ^a   Gilliet, Michel ^a   Michaelis, Sonja ^a   Schärer, Leo ^a   Burg, Günter ^a   Dummer, Reinhard ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Cutaneous B cell lymphoma; Interferon; Intra lesional injection; Marginal zone B cell lymphoma

Indexed keywords

ALPHA2A INTERFERON; DOXYCYCLINE; PARACETAMOL; RECOMBINANT ALPHA2A INTERFERON;

ADULT; AGE; AGED; ARTICLE; B CELL LYMPHOMA; CANCER LOCALIZATION; CANCER REGRESSION; CANCER RELAPSE; CLINICAL ARTICLE; DRUG ADMINISTRATION ROUTE; DRUG FEVER; ERYTHEMA; FEMALE; HEADACHE; HUMAN; LOW DRUG DOSE; MALAISE; MALE; PRIORITY JOURNAL; PRURITUS; PSORIASIS; SKIN LYMPHOMA; TREATMENT CONTRAINDICATION;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERFERON ALFA-2A; LYMPHOMA, MUCOSA-ASSOCIATED LYMPHOID TISSUE; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; SKIN NEOPLASMS;

EID: 33744906556     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190500399698     Document Type: Article

References (27)

1. Willemze, R and Jaffe, E and Burg, G and Cerroni, L and Berti, E and Swerdlow, S and (2005) WHO-EORTC classification for cutaneous lymphomas Blood, 105, pp. 3768-3785.
2. Hoefnagel, J and Vermeer, M and Jansen, P and Fleuren, G and Meijer, C and Willemze, R. (2003) Bcl-2, Bcl-6 and CD10 expression in cutaneous B-cell lymphoma: Further support for a follicle centre cell origin and differential diagnostic significance British Journal of Dermatology, 149, pp. 1183-1191.
3. Dummer, R and Kempf, W and Hess Schmid, M and Haffner, A and Burg, G. (2003) Therapy of cutaneous lymphoma - current practice and future developments Onkologie, 26, pp. 366-372.
4. Heinzerling, L and Dummer, R and Kempf, W and Schmid, M and Burg, G. (2000) Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma Archives of Dermatology, 136, pp. 374-378.
5. Rubegni, P and De Aloe, G and Pianigiani, E and Lazzi, S and Fimiani, M. (1999) Primary cutaneous B-cell lymphoma: Treatment with low dose intralesional recombinant interferon-alpha 2A Journal of the European Academy of Dermatology & Venereology, 12, pp. 70-71.
6. Wollina, U. (1998) Complete response of a primary cutaneous T-cell-rich B cell lymphoma treated with interferon alpha2a Journal of Cancer Research & Clinical Oncology, 124, pp. 127-129.
7. Kutting, B and Bonsmann, G and Metze, D and Luger, T and Cerroni, L. (1997) Borrelia burgdorferi-associated primary cutaneous B cell lymphoma: Complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a Journal of the American Academy of Dermatology, 36, pp. 311-314.
8. Zenone, T and Catimel, G and Barbet, N and Clavel, M. (1994) Complete remission of a primary cutaneous B cell lymphoma treated with intralesional recombinant interferon alpha-2a European Journal of Cancer, 30A, pp. 246-247.
9. Wollina, U and Hahnfeld, S and Kosmehl, H. (1999) Primary cutaneous marginal center lymphoma - complete remission induced by interferon alpha2a Journal of Cancer Research & Clinical Oncology, 125, pp. 305-308.
10. Zenahlik, P and Fink-Puches, R and Kapp, K and Kerl, H and Cerroni, L. (2000) [Therapy of primary cutaneous B-cell lymphomas] Hautarzt, 51, pp. 19-24.
11. Brierley, M and Fish, E. (2002) Review: IFN-alpha/beta receptor interactions to biologic outcomes: Understanding the circuitry Journal of Interferon & Cytokine Research, 22, pp. 835-845.
12. Platanias, L. (2005) Mechanisms of type-I- and type-II-interferon-mediated signalling Natural Reviews in Immunology, 5, pp. 375-386.
13. von Marschall, Z and Scholz, A and Cramer, T and Schafer, G and Schirner, M and Oberg, K and (2003) Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis Journal of the National Cancer Institute, 95, pp. 437-448.
14. Brassard, D and Grace, M and Bordens, R. (2002) Interferon-alpha as an immunotherapeutic protein Journal of Leukocyte Biology, 71, pp. 565-581.
15. Krown, S and Real, F and Cunningham-Rundles, S and Myskowski, P and Koziner, B and Fein, S and (1983) Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma New England Journal of Medicine, 308, pp. 1071-1076.
16. Bunn, P, Jr and Ihde, D and Foon, K. (1987) Recombinant interferon alfa-2a, an active agent in advanced cutaneous T-cell lymphomas International Journal of Cancer Supplement, 1, pp. 9-13.
17. Agarwala, S and Kirkwood, J. (1998) Adjuvant interferon treatment for melanoma Hematology & Oncology Clinics of North America, 12, pp. 823-833.
18. Edwards, L and Berman, B and Rapini, R and Whiting, D and Tyring, S and Greenway, H, Jr and (1992) Treatment of cutaneous squamous cell carcinomas by intralesional interferon alfa-2b therapy Archives of Dermatology, 128, pp. 1486-1489.
19. Tsimberidou, A and Giles, F and Romaguera, J and Duvic, M and Kurzrock, R. (2004) Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies Cancer, 100, pp. 574-580.
20. Bonkovsky, H and Clifford, B and Smith, L and Allan, C and Banner, B. (1996) High-dose interferon-alpha 2b for re-treatment of nonresponders or relapsing patients with chronic hepatitis C. A controlled randomized trial Digestive Disease Science, 41, pp. 149-154.
21. Iino, S. (1993) High dose interferon treatment in chronic hepatitis C Gut, 34(2 Suppl), pp. S114-S118.
22. Davis, G and Balart, L and Schiff, E and Lindsay, K and Bodenheimer, H, Jr and Perrillo, R and (1989) Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group New England Journal of Medicine, 321, pp. 1501-1506.
23. Gisslinger, H and Svoboda, T and Clodi, M and Gilly, B and Ludwig, H and Havelec, L and Luger, A. (1993) Interferon-alpha stimulates the hypothalamic-pituitary-adrenal axis in vivo and in vitro Neuroendocrinology, 57, pp. 489-495.
24. Bocci, V. (1988) Central nervous system toxicity of interferons and other cytokines Journal of Biologically Regulated Homeostasis Agents, 2, pp. 107-118.
25. Gauci, L. (1987) Management of cancer patients receiving interferon alfa-2a International Journal of Cancer Supplement, 1, pp. 21-30.
26. Dummer, R and Hassel, J and Fellenberg, F and Eichmuller, S and Maier, T and Slos, P and (2004) Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas Blood, 104, pp. 1631-1638.
27. Heinzerling, L and Urbanek, M and Funk, J and Peker, S and Bleck, O and Neuber, K and (2000) Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma Cancer, 89, pp. 1835-1844.